Hepatitis E Breakthrough: Drug in Trials Shows Promise Against Virus | News-Medical.net

Hepatitis C Drug Shows Promise Against Deadly Hepatitis E

A drug currently in clinical trials for hepatitis C virus (HCV) has demonstrated the ability to prevent replication of the hepatitis E virus (HEV), offering a potential breakthrough in the treatment of a disease that causes approximately 70,000 deaths annually worldwide. The findings, published in the journal Gut on March 6, 2026, identify bemnifosbuvir, a nucleotide/nucleoside analogue, as a promising candidate for treating HEV infections.

Currently, Notice no specific antiviral drugs or vaccines available to treat hepatitis E, leaving patients, particularly those with compromised immune systems or pregnant women, vulnerable to severe complications. Acute infections typically resolve on their own in individuals with healthy immune function, but can become chronic in those with weakened immunity. The identification of bemnifosbuvir represents a significant step forward in addressing this unmet medical need.

International Collaboration Yields Key Discovery

The research was the result of a collaborative effort involving scientists from Ruhr University Bochum in Germany, the Dao Thi Lab at Heidelberg University Hospital’s Center for Integrative Infectious Disease Research (CIID), and the Lin Wang Lab at Peking University in China. Researchers screened a library of commercially available nucleotide/nucleoside analogues – synthetic molecules resembling the building blocks of DNA and RNA – to identify compounds capable of inhibiting HEV replication.

Dr. Mara Klöhn of Ruhr University Bochum explained that these analogues mimic the genetic material of both the host, and viruses. The team employed a novel reporter virus containing a fluorescent molecule to track viral replication. By infecting cell cultures with HEV carrying this reporter gene and then introducing the candidate compounds, they were able to observe whether the virus continued to replicate based on fluorescence levels. “With bemnifosbuvir we were able to see that the virus no longer replicated, while the treated cells remained healthy,” reported Jungen Hu from Heidelberg University.

Bemnifosbuvir’s Dual Action and Potential for Rapid Availability

Animal studies conducted by the Chinese research team confirmed the efficacy of bemnifosbuvir against HEV and associated liver inflammation. Crucially, because the drug is already undergoing clinical trials for HCV, researchers are optimistic that it could become available for hepatitis E treatment relatively quickly, potentially through “off-label” use if the HCV trials are successful. This pathway could significantly shorten the timeline for access compared to developing a completely new drug.

The development of bemnifosbuvir builds on decades of research into hepatitis E. While the virus was first identified following epidemic outbreaks in 1955-1956, intensive study didn’t begin until many years later. A vaccine exists, but is currently only licensed for use in China, highlighting the global disparity in access to preventative measures.

Looking Ahead

The success of bemnifosbuvir in preclinical models offers a beacon of hope for the treatment of hepatitis E. The ongoing clinical trials for hepatitis C will be closely watched, as positive results could pave the way for its broader application against this often-fatal viral infection. Further research will be needed to optimize dosage and treatment regimens for HEV, but the identification of this compound represents a major advancement in the fight against a neglected tropical disease.